TY  - JOUR
AU  - Kadmiri, Nadia El
PY  - 2024
DA  - 2024/08/07
TI  - Tau-Targeted Immunotherapy for Alzheimer's Disease: Insight into Clinical Trials
JO  - OBM Neurobiology
SP  - 238
VL  - 08
IS  - 03
AB  - The use of immunotherapy as a therapeutic approach to Alzheimer's Disease (AD) is gaining rapid interest, with the primary goal of targeting abnormalities that impact neuronal viability through specific antibodies. Currently, clinical strategies focus intensively on targeting the two main pathologies associated with AD, beta-amyloid (Ab) and tau. This review examines ongoing research in the realm of tau immunotherapy, including clinical trials that demonstrate promising potential for halting AD progression. Several trials are underway, focusing on improving tau-targeted immunotherapy tools based on passive and active immunization protocols. Tau-targeted therapies have proven relevant and demonstrated safety and efficacy in both animal models and human clinical trials. Some studies have demonstrated a reduction in tau protein aggregation in animal models, highlighting a potential mechanism by which these antibodies inhibit the spread of tau protein in the extracellular space. Recent discoveries have highlighted the potential role of tau-targeting therapy with antibodies and have revealed significant promise in treating pathological tau in AD.
SN  - 2573-4407
UR  - https://doi.org/10.21926/obm.neurobiol.2403238
DO  - 10.21926/obm.neurobiol.2403238
ID  - Kadmiri2024
ER  -